Research Studies for MDD and Schizophrenia

Neurocrine Biosciences is currently enrolling for the TERPSIS and SAVITRI Studies on major depressive disorder (MDD) and the Journey Studies on schizophrenia. This information is intended for a US audience. If you have patients who may be eligible for the TERPSIS, SAVITRI, or Journey Studies, consider sharing the study website with them.

Studies for Major Depressive Disorder

The TERPSIS Study is a phase 2, double-blind, placebo-controlled research study evaluating the safety and efficacy of once-weekly oral NBI-1065846 in participants with MDD who are on antidepressant medication(s) but are experiencing anhedonia. Participants in the TERPSIS Study who are currently on antidepressant medication(s) will be able to stay on their current antidepressant(s) while in the research study.

The SAVITRI Study is a phase 2, double-blind, placebo-controlled research study evaluating the safety and efficacy of once-daily oral NBI-1065845 in improving symptoms of MDD in patients who are having an inadequate response to antidepressant medication(s). Participants in the SAVITRI Study who are currently on antidepressant medication(s) will be able to stay on their current antidepressant(s) while in the research study.

Patients may qualify for the TERPSIS and SAVITRI Studies if they:

• Are 18 to 65 years of age (inclusive)
• Have a confirmed diagnosis of MDD
• Are currently on or have previously been on antidepressant medication(s)
• Are not pregnant or breastfeeding or planning to become pregnant during the study

To qualify for SAVITRI, patients must also have had an inadequate response to up to 5 oral antidepressant medications.

Additional eligibility criteria apply.